hritis Research Center at the University of North Carolina at Chapel Hill announced additional findings from their previously reported 1,154-patient longitudinal study to evaluate the role of genetic factors in osteoarthritis (OA) progression. The new data, which was presented at the American College of Rheumatology Annual Scientific Meeting indicated patients with radiographic signs of early knee osteoarthritis were genetically different from those without radiographic signs of the disease and progressed to moderate or severe OA at a much greater frequency. The findings could also enable at-risk patients to receive critical early intervention to offset complications associated with moderate and severe disease.
Conference Call and Webcast InformationInterleukin Genetics, Inc. will host a live conference call and webcast today at 4:30 p.m. EDT. To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 (international). The live webcast will be available at the Investors section of the Company's website, www.ilgenetics.com.
The webcast will be archived following the call at www.ilgenetics.com.
About Interleukin Genetics Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics' flagship products include its proprietary PST® genetic risk panel for
Page: 1 2 3 4 5 6 7 Related biology technology :1
|SOURCE Interleukin Genetics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Interleukin Genetics, Inc. to Present at Biotech Showcase 20112
. Interleukin Genetics, Inc. Receives Delisting Notification from NYSE Amex3
. Interleukin Genetics to Present at Upcoming Biotech Industry Meetings4
. Interleukin Genetics to Present at the 12th Annual BIO CEO Conference5
. Continued Uptake of TNF-Alpha Inhibitors and Interleukin Inhibitors Will Drive $2.2 Billion Growth in the Psoriasis Drug Market6
. Interleukin Genetics Reports Second Quarter 2009 Financial Results7
. Interleukin Genetics Announces Conference Call To Discuss Second Quarter 2009 Results8
. Interleukin Genetics to Present at the 2009 BIO Business Forum9
. Interleukin Genetics Reports Fourth Quarter and Year End 2008 Financial Results10
. Interleukin Genetics Receives Notification of Failure to Meet Continued Listing Standard Section 1003(a)(iii)11
. Interleukin Genetics Appoints Todd Anthony Walker as Vice President, Marketing